UCB (OTC:UCBJF) Stock, Quote.Headers.trade-ideas

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Johnson & Johnson Inc. JNJ

Biotech

Large Cap

News

Health Care

General

PTGX

UCBJF

UCBJY

Protagonist and J&amp;J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Protagonist/Johnson &amp; Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

Analyst Color

Government

Analyst Ratings

Movers

Trading Ideas

ARGX

GILD

REGN

RHHBY

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Jakarta,-,Sept,12,2024:,National,Health,Service,(nhs),England,Signboard

Eurozone

AMGN

BIIB

DSNKY

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&amp;D investment and falling global competitiveness.

Pharmaceutical Firms Say UK Investment Is &#39;Unlikely&#39; Unless Payment Levy Is Adressed

UCB SA

Comments

UCB

UCB (OTC:UCBJF) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell